In the race for novel oral drugs to treat anemia of chronic kidney disease, AstraZeneca and FibroGen’s roxadustat held the front-runner position for quite some time. But as that program has now ...
August 4th 2020EP. 14: Future Treatment of Anemia in CKD: Impact of HIF Stabilizers August 4th 2020EP. 15: Future Management of Anemia in CKD ...
Could the third time be the charm for an oral HIF-PH inhibitor in the U.S.? GlaxoSmithKline certainly hopes so, with its potential first-in-class medicine now officially up for a decision at the FDA ...
GSK plc may have pushed the door open Oct. 26 for the use of a new class of oral drugs to treat anemia in U.S. patients with chronic kidney disease who are dialysis dependent. The U.S. FDA’s ...
Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe ...
Please provide your email address to receive an email when new articles are posted on . Jay B. Wish, MD: The quality of life was terrible. Patients felt tired all the time; they had no energy, no ...
A person with anemia of chronic disease has decreased red blood cells despite having “normal” or increased iron stores in their body. It can occur in people with underlying inflammatory conditions, ...
Dr. Anju Goel, MD, MPH, is a public health consultant and physician with more than 10 years of experience in the California public health system. Heavy periods that cause blood loss can lead to iron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback